Neuren Pharmaceuticals Limited
NURPF
$10.97
-$1.31-10.67%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -2.75% | 689.61% | |||
| Total Other Revenue | -2.74% | -- | |||
| Total Revenue | -2.75% | 704.61% | |||
| Cost of Revenue | -2.75% | -14.28% | |||
| Gross Profit | -2.75% | 2,702.09% | |||
| SG&A Expenses | -2.74% | -0.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.75% | -12.65% | |||
| Operating Income | -2.75% | 4,280.64% | |||
| Income Before Tax | -2.75% | 1,368.94% | |||
| Income Tax Expenses | -2.75% | 884.87% | |||
| Earnings from Continuing Operations | -2.75% | 1,600.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.75% | 1,600.06% | |||
| EBIT | -2.75% | 4,280.64% | |||
| EBITDA | -2.75% | 4,269.17% | |||
| EPS Basic | -2.76% | 1,596.62% | |||
| Normalized Basic EPS | -2.75% | 1,367.02% | |||
| EPS Diluted | -2.74% | 1,600.00% | |||
| Normalized Diluted EPS | -2.74% | 1,373.12% | |||
| Average Basic Shares Outstanding | 0.00% | 0.15% | |||
| Average Diluted Shares Outstanding | 0.00% | -0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||